Themis Medicare Past Earnings Performance
Past criteria checks 2/6
Themis Medicare has been growing earnings at an average annual rate of 29.7%, while the Pharmaceuticals industry saw earnings growing at 16% annually. Revenues have been growing at an average rate of 16.9% per year. Themis Medicare's return on equity is 11.5%, and it has net margins of 11.3%.
Key information
29.7%
Earnings growth rate
29.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 16.9% |
| Return on equity | 11.5% |
| Net Margin | 11.3% |
| Next Earnings Update | 30 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Themis Medicare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 3,865 | 435 | 824 | 0 |
| 31 Dec 23 | 3,640 | 453 | 896 | 0 |
| 30 Sep 23 | 3,703 | 512 | 863 | 0 |
| 30 Jun 23 | 3,565 | 577 | 700 | 0 |
| 31 Mar 23 | 3,543 | 569 | 781 | 0 |
| 31 Dec 22 | 3,540 | 584 | 711 | 0 |
| 30 Sep 22 | 3,602 | 576 | 677 | 0 |
| 30 Jun 22 | 3,765 | 591 | 575 | 0 |
| 31 Mar 22 | 3,946 | 729 | 610 | 0 |
| 31 Dec 21 | 3,766 | 710 | 529 | 0 |
| 30 Sep 21 | 3,472 | 703 | 498 | 0 |
| 30 Jun 21 | 2,947 | 591 | 407 | 0 |
| 31 Mar 21 | 2,307 | 357 | 444 | 0 |
| 31 Dec 20 | 2,151 | 349 | 456 | 0 |
| 30 Sep 20 | 2,033 | 338 | 467 | 0 |
| 30 Jun 20 | 1,987 | 274 | 436 | 0 |
| 31 Mar 20 | 2,016 | 248 | 491 | 0 |
| 31 Dec 19 | 1,911 | 61 | 521 | 0 |
| 30 Sep 19 | 1,855 | -45 | 522 | 0 |
| 30 Jun 19 | 1,846 | -64 | 527 | 0 |
| 31 Mar 19 | 1,838 | -107 | 541 | 0 |
| 31 Dec 18 | 2,002 | 54 | 564 | 0 |
| 30 Sep 18 | 2,022 | 78 | 569 | 0 |
| 30 Jun 18 | 2,063 | 101 | 560 | 0 |
| 31 Mar 18 | 2,095 | 113 | 546 | 0 |
| 31 Dec 17 | 2,354 | 105 | 545 | 0 |
| 30 Sep 17 | 2,399 | 143 | 525 | 0 |
| 30 Jun 17 | 2,323 | 142 | 504 | 0 |
| 31 Mar 17 | 2,167 | 160 | 487 | 0 |
| 31 Dec 16 | 2,438 | 211 | 468 | 0 |
| 30 Sep 16 | 2,368 | 212 | 456 | 0 |
| 30 Jun 16 | 2,404 | 208 | 386 | 0 |
| 31 Mar 16 | 2,324 | 163 | 417 | 0 |
| 31 Dec 15 | 2,287 | 155 | 603 | 0 |
| 30 Sep 15 | 2,227 | 142 | 593 | 0 |
| 30 Jun 15 | 2,022 | 71 | 334 | 0 |
| 31 Mar 15 | 2,019 | 62 | 361 | 0 |
| 31 Mar 14 | 1,951 | 27 | 526 | 0 |
Quality Earnings: 530199 has high quality earnings.
Growing Profit Margin: 530199's current net profit margins (11.3%) are lower than last year (16.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 530199 has become profitable over the past 5 years, growing earnings by 29.7% per year.
Accelerating Growth: 530199's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 530199 had negative earnings growth (-23.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (22.5%).
Return on Equity
High ROE: 530199's Return on Equity (11.5%) is considered low.